

TITLE: **MICROFILTRATION AND/OR ULTRAFILTRATION
PROCESS FOR RECOVERY OF TARGET MOLECULES
FROM POLYDISPERSE LIQUIDS**

INVENTORS: **GEORGES BELFORT AND GAUTAM LAL BARUAH**

DOCKET NO.: **18001/5062 (RPI-806)**

MICROFILTRATION AND/OR ULTRAFILTRATION PROCESS FOR RECOVERY OF TARGET MOLECULES FROM POLYDISPERSE LIQUIDS

FIELD OF THE INVENTION

5

[0001] This application claims the benefit of U.S. Provisional Patent Application Serial Nos. 60/464,497, filed April 22, 2003 and 60/527,919, filed December 8, 2003.

10 **[0002]** The present invention relates to a microfiltration and/or ultrafiltration process for recovery of target molecules from polydisperse liquids.

BACKGROUND OF THE INVENTION

15 **[0003]** The transgenic process is an economically attractive method of producing large amounts of human therapeutic proteins (John et al., "Expression of an Engineered Form of Recombinant Procollagen in Mouse Milk," *Nature Biotech.* 17:385-389 (1999); Kreeger, "Transgenic Mammals Likely to Transform Drug Making," *The Scientist*, 11(15):11 (1997); McKee et al., "Production of Biologically Active Salmon Calcitonin in the Milk of Transgenic Rabbits," *Nature Biotech.* 20 16:647-651 (1998); Pollock et al., "Transgenic Milk as a Method for the Production of Recombinant Antibodies," *J. Immunol. Methods* 231:147-57 (1998); and Prunkard et al., "High-Level Expression of Recombinant Human Fibrinogen in the Milk of Transgenic Mice," *Nature Biotech.* 14:867-71 (1996)). This involves the creation of genetically altered animals and plants such that the desired heterologous protein is 25 recoverable in their milk, eggs, fruit, etc. A DNA construct that encodes the target human protein, is inserted into a goat cell line by transfection. The transfected transgenic cell is then fused with an enucleated oocyte by electrofusion. After 24-48 hours in culture, the embryo is transferred to a surrogate mother. The putative transgenic animals are identified by screening the offspring for the transgene. After 30 the selected females mature, they are bred and the milk produced after gestation is tested for protein expression.

[0004] Transgenic versions of therapeutic proteins, implicated in chronic diseases, like human monoclonal antibodies, tissue plasminogen activator,

antithrombin III, and human lactoferrin are in various stages of FDA approval (John et al., "Expression of an Engineered Form of Recombinant Procollagen in Mouse Milk," *Nature Biotech.* 17:385-89 (1999); Kreeger, "Transgenic Mammals Likely to Transform Drug Making," *The Scientist*, 11(15):11 (1997); McKee et al., "Production of Biologically Active Salmon Calcitonin in the Milk of Transgenic Rabbits," *Nature Biotech.* 16:647-51 (1998); Pollock et al., "Transgenic Milk as a Method for the Production of Recombinant Antibodies," *J. Immunol. Methods* 231:147-157 (1998); and Prunkard et al., "High-Level Expression of Recombinant Human Fibrinogen in the Milk of Transgenic Mice," *Nature Biotech.* 14:867-871 (1996)). These products are being developed as treatments for arthritis, HIV/AIDS, cancer, and autoimmune diseases. One limitation of the transgenic process is the long lag-time between cloning and production (~ 18 months). However, recent developments have purportedly cut this time in half.

[0005] The complexity of milk combined with the low concentration of target protein complicates the recovery process from transgenic milk. Whole milk consists of more than 100,000 different molecules dispersed in three phases namely, lipid, casein, and whey (Tetra Pak Processing Systems, AB, S-221 86, *Dairy Processing Handbook*, Lund Sweden:Verlag. 452 p. (1995)) and heterologous recombinant proteins can be overproduced in the range of 0.2 to 1 wt. %. Traditional methods used by the dairy industry to isolate proteins from milk involving pasteurization followed by enzymatic coagulation or acid precipitation at pH 4.6 (pI of casein) are unsuitable for the recovery of heterologous proteins because they can be temperature and pH sensitive. Additionally, the coagulation process can trap a large amount of the target protein within the casein pellets resulting in poor yields (Morcol et al., "Model Process for Removal of Caseins from Milk of Transgenic Animals," *Biotechnol. Prog.* 17:577-582 (2001)). Transgenic milk is neither pasteurized nor homogenized in order to prevent damage and loss of the target heterologous proteins. In non-homogenized transgenic milk, the liquid fat droplets, ranging from 0.1 to 20 μ m in diameter (Goff et al., "Dairy Chemistry and Physics," In: Hui YH, editor, *Dairy Science and Technology Handbook*, Vol. 1, Principles and Properties. New York:VCH. p 1-81 (1993)), are encased by a 8 to 10 nm thick membrane called the native fat globule membrane (FGM). The FGM is composed of phospholipids and proteins and is

characterized by a very low interfacial surface tension, 1 to 2.5 mN/m, between the fat globules and the serum phase. This prevents the globules from flocculation and from enzymatic degradation. Homogenization breaks up the fat globules causing disruption of the native FGM, which allows serum proteins and casein micelles to

5 freely adsorb onto the exposed fat globules. This results in loss of heterologous proteins through adsorption (Meade et al., "Recombinant Protein Expression in Transgenic Mice," In: Fernandez J, Hoeffler J, editors, *Gene Expression Systems: Using Nature for the Art of Expression*, Carlsblad:Academic Press. p 399-427 (1998)). The latter effect is expected to reduce the yield of target protein and the

10 former effect increases membrane fouling because of a lower value of back-transport due to shear or inertial lift of small fat globules. The casein micelle is a roughly spherical, fairly swollen particle of 0.1 to 0.3 μm diameter with a hairy outer layer (Walstra, "Casein Sub-Micelles: Do They Exist?," *Int. Dairy J.* 9:189-192 (1999); McMahon, "Rethinking Casein Micelle Structure Using Electron Microscopy," *J. Dairy Sci.* 81:2985-2993 (1998)). The hairy layer is comprised of C-terminal ends of κ -casein. This prevents further aggregation of micelles and flocculation by steric and electrostatic repulsion at pH values higher than 4.6, the pI of casein. Thus, at the physiological pH of milk, 6.4-6.6, the casein micelles predominantly exist as distinct particles of a size range comparable to the mean pore size (0.1 μm) of the poly(ether

15 sulfone) microfiltration membrane used here. This is expected to result in a low shear-induced diffusion coefficient as well as fouling by pore blockage and cake formation, especially at low shear rates. Fat globules and casein micelles are retained in whole milk microfiltration, whereas the product protein permeates through the membrane along with the whey proteins, minerals, and sugars. This is corroborated by

20 polyacrylamide gel electrophoresis studies of permeate samples of milk clarified by microfiltration with a 0.2 μm average pore size ceramic membrane which indicate negligible casein transmission through the membrane.

25

[0006] The present invention is directed to an improved procedure for recovering target molecules from polydisperse liquids, including recovering

30 components from milk.

SUMMARY OF THE INVENTION

[0007] One embodiment of the present invention relates to a method of recovering a target entity from a polydisperse liquid. This method includes 5 subjecting the polydisperse liquid to a microfiltration process utilizing a microfiltration membrane under conditions effective to permit the target entity to pass through the microfiltration membrane. The microfiltered polydisperse liquid is then subjected to an ultrafiltration process utilizing an ultrafiltration membrane under conditions effective to permit the target entity to be retained on the ultrafiltration 10 membrane. This method is effective to cause the target entity to be recovered from the polydisperse liquid in a yield of greater than 75% and a purity of greater than 80%.

[0008] Another embodiment of the present invention is directed to a method of recovering a target entity from a polydisperse liquid by subjecting the polydisperse 15 liquid to a microfiltration process. The microfiltration process utilizes a microfiltration membrane under conditions effective to permit the target entity to pass through the microfiltration membrane as a permeate, where the target entity in the permeate is greater than 90% of the target entity present in the polydisperse liquid and the target entity is present in the permeate in a concentration of 7-10%.

20 [0009] Yet another embodiment of the present invention is directed to a method of recovering a target entity from a polydisperse liquid by subjecting the polydisperse liquid to an ultrafiltration process. The ultrafiltration process utilizes an ultrafiltration membrane under conditions effective to permit the target entity to be retained on the ultrafiltration membrane at a pH which differs from the target entity's 25 pI.

[0010] A two step microfiltration and ultrafiltration process has been developed for achieving high yield and purity of proteins from high fouling, polydisperse suspensions of biological origin. One such suspension is transgenic whole milk which includes high fouling fat, somatic cells, casein, etc. apart from the 30 target entity. Recovery is fraught with challenges due to the polydispersity and molecular diversity of whole milk. This two step process results in yields in excess of 75% and purity of 80% of a heterologous therapeutic protein expressed in transgenic milk.

[0011] The first step can involve the use of a short helical hollow fiber microfiltration module (average pore size 0.1 micrometers) with approximately uniform transmembrane pressure along the length, achieved by permeate circulation in a co-axial direction (called coflow) as the retentate flow. This ensures that the 5 transmission of the target protein through the membrane is enhanced due to the dual advantages of low transmembrane pressure leading to a sparse cake, and hence higher transmission, as well as the high shear rates inherent in the helical module due to self-cleaning Dean vortices. Additionally, the use of a short module allows operation at higher shear rates within the design pressure of the membrane module. A crucial 10 aspect of this step is operation at the isoelectric pH of the target protein which minimizes charge exclusion of the target protein from membrane pores and cake interstices. This step results in a clear permeate consisting of over 90% of the target protein along with other milk whey proteins, salts, and sugars. The concentration of IgG is in the range of 7 to 10% of the total proteins in TGM. Microfiltration (MF) in 15 the diafiltration mode increases to around 7 to 20%, depending on the extent of pre-concentration prior to diafiltration.

[0012] The second step involves an ultrafiltration (UF) scheme to raise the purity, for example, of IgG from 7% to 80% with a yield of 80%. As a 95% yield of target protein was achieved in the MF stage, this resulted in a two step MF/UF 20 process with an overall yield of 75% and a purity of 80% for the target protein. Tangential flow UF experiments in diafiltration mode were conducted with 100 kD 25 cellulosic membranes to evaluate the optimal pH, ionic strength, and uniform transmembrane pressure (TMP). The TMP was kept uniform by permeate circulation in co-flow mode. The traditional approach of conducting the UF close to the pI of the predominant whey proteins (15 – 40 kD, pI - 5.2) to facilitate their ready passage, whereas the bulkier (155 kD) and charged IgG is retained, could not be applied 30 because of precipitation of residual casein at pH values lower than 8.5. Instead, the packing characteristics of the cake layer on the membrane wall was utilized at a pH of 10.75 and 15 mM NaCl to achieve a selectivity of 18, which is sufficient to meet the stated goals of purity and yield for this difficult separation.

[0013] The distinctive features of the MF step are the choice of a novel short helical hollow fiber membrane module in lieu of commercially available linear

versions, operating pH at the isoelectric pH of the target protein, operation at nearly uniform low transmembrane pressure less than or equal to 2 psi, low axial velocity of 1 m/s, very low permeation flux of less than 30 lmh, and a rapid acid free cleaning regimen of just 45 minutes to ensure full membrane cleaning for reuse. The 5 distinctive features of the UF step are the optimization of ionic strength, pH, and permeation flux to achieve protein separation at a pH different from the pI of any of the proteins involved by using concentration polarization and the correct amount of charge shielding.

[0014]

10

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1A shows the linear and new coiled hollow fiber design. Figure 1B is a flow sheet of the lab-scale hollow fiber microfiltration system showing two separate flow systems.

15 **[0016]** Figure 2 is a schematic drawing of a microfiltration system.

[0017] Figure 3 shows the hydraulic permeability versus run number for the short helical hollow fiber module (H-3a) after several cleaning cycles.

20 **[0018]** Figure 4A shows the average permeation flux, while Figure 4B shows the IgG yield versus pH for the short helical hollow fiber module (H-3a) at a uniform TMP of 2.5 psi, an axial velocity of 1.1 m/sec ($Re \approx 1075$), a 1X milk concentration, and the number of diavolumes ($N_d = 4$).

[0019] Figure 5A shows the average permeation flux, while Figure 5B shows the IgG yield versus uniform TMP for the short helical hollow fiber module at 1.1 m/s axial velocity ($Re \approx 1075$), pH = 9.0, 1X milk conc., and $N_d = 4$.

25 **[0020]** Figure 6 is a schematic of three different operating regimes during microfiltration of poly-disperse suspensions. Regime I: pore constriction. Regime II: cake consolidation. Regime III: Pressure independent flux.

[0021] Figure 7A shows the yield, while Figure 7B shows the duration divided by the milk concentration versus the milk concentration for the short helical (H-3a) 30 and linear (L-3a) hollow fiber module at 1.0 m/s axial velocity ($Re \approx 977$), pH = 9.0, ≤ 2 psi uniform TMP, and $N_d = 4$ for 1X, 5 for 1.25X, and 6 for higher milk concentrations.

[0022] Figure 8 shows the yield versus axial velocity ($Re \approx 830 - 1170$) for the short helical (H-3a) hollow fiber module at $pH = 9.0$, ≤ 2 psi uniform TMP, 1X milk concentration, and $N_d = 4$.

[0023] Figure 9 is a schematic drawing of an ultrafiltration system.

5 [0024] Figure 10 is a plot of flux (lmh) versus transmembrane pressure (psi).

[0025] Figure 11 is a plot of selectivity versus NaCl concentration (mM).

[0026] Figure 12 is a plot of selectivity versus flux (lmh).

[0027] Figure 13 is a plot of IgG yield versus flux (lmh).

[0028] Figure 14 is a plot of IgG purification factor versus flux (lmh).

10 [0029] Figure 15 is a plot of IgG purification factor versus time (hours) and IgG yield versus time (hours).

DETAILED DESCRIPTION OF THE INVENTION

15 [0030] One embodiment of the present invention relates to a method of recovering a target entity from a polydisperse liquid. This method includes subjecting the polydisperse liquid to a microfiltration process utilizing a microfiltration membrane under conditions effective to permit the target entity to pass through the microfiltration membrane. The microfiltered polydisperse liquid is then subjected to an ultrafiltration process utilizing an ultrafiltration membrane under conditions effective to permit the target entity to be retained on the ultrafiltration membrane. This method is effective to cause the target entity to be recovered from the polydisperse liquid in a yield of greater than 75% and a purity of greater than 80%.

20 [0031] Most existing theories of MF and UF deal with monodisperse suspensions and the pressure independent regime (Belfort et al., "The Behavior of Suspensions and Macromolecular Solutions in Crossflow Microfiltration," *J. Membr. Sci.* 96:1-58 (1994) and Zeman et al., *Microfiltration and Ultrafiltration Principles and Applications*. Marcel Dekker, Inc., New York, (1996), which are hereby incorporated by reference in their entirety), where the dominant resistance is provided by the cake on the membrane wall. Both solvent and solute transport through the membrane are governed by the balance between convection of solutes to the

membrane and the back transport of solutes from the membrane wall to the bulk solution by Brownian diffusion, shear induced diffusion or inertial lift mechanisms, and the sieving through the membrane wall. These theories do not predict solute transport, ignore solute-solute and solute-wall interactions, and are valid only for the

5 laminar flow regimes.

[0032] Applicants have recently developed a theory called the Aggregate transport model (see PCT Application Serial No. PCT/US03/25230, filed August 13, 2003, which is hereby incorporated by reference in its entirety), that addresses two crucial aspects missing in the earlier theories: (a) *a priori* prediction of solute 10 transport and (b) solute polydispersity, which is the rule rather than the exception in real suspensions. This approach builds upon the earlier back-transport models, by incorporating an iterative technique which relates the nature of the cake on the membrane wall to the propensity of back transport of various solutes. Packing constraints, based on geometry, are utilized to determine the nature of the cake. The 15 lowest propensity to back-transport gives the first approximation for the permeation flux. The interstices of the cake are likened to membrane pores. The solute partitioning coefficient, ϕ , is evaluated as a function of the ratio of the transmitting solute to the diameter of the cake interstice based on hard sphere interactions. The hindrance factor, K_c , is evaluated based on simplified versions (Zeman et al., 20 "Polymer Solute Rejection by Ultrafiltration Membranes," *Synthetic Membranes vol. II. Hyperfiltration and Ultrafiltration Uses* (A. F. Turbak, ed.), ACS Symposium Series No. 54, American Chemical Society, Washington, D.C., p. 412 (1981), which is hereby incorporated by reference in its entirety). Thus,

$$\phi = (1-\lambda)^2 \quad (1)$$

25 $K_c = [2 - (1-\lambda)^2] \exp(-0.7146\lambda^2) \quad (2)$

For high Peclet numbers, the solute flux is thus evaluated by using the convection equation,

$$N_s = \phi K_c V C_w \quad (3)$$

For operation in the pressure dependent regime, the membrane determines both 30 solvent and solute transport. For the idealized geometry of a spherical solute and cylindrical pore, the general expression for the solute partitioning coefficient is (Zydney et al., "Protein Transport Through Porous Membranes: Effect of Colloidal

Interactions," *Coll. Surf. A.* 138:133-143 (1998), which is hereby incorporated by reference in its entirety), $\phi = 2/r_p^2$.

5 [0033] The microfiltration process is preferably carried out using flow around a curved microporous walled membrane channel. Typically, this is achieved with a Dean vortex in a helical hollow fiber membrane module, as shown in Figure 1A. This procedure is fully described in U.S. Patent Nos. 5,626,758 and Re 37,759 to Belfort, et. al., which are hereby incorporated by reference in their entirety. The Dean vortex is of sufficient strength to disturb build-up of solute and particles near a surface of the
10 membrane.

15 [0034] The microfiltration process is carried out using co-flow of permeate and retentate. As shown in Figure 1B, milk M enters milk tank 2 from which it is discharged by retentate pump 3 into microfiltration unit 4. Retentate R is returned from microfiltration unit 4 into milk tank 2 after passing through flow indicator 18. Liquid from permeate tank 6 is withdrawn by permeate circulation pump 8 and passed into microfiltration unit 4. Permeate P is then returned to permeate tank 6. The pressure drop of retentate across microfiltration unit 4 is measured by pressure indicators 10 and 12, while the pressure drop of permeate across microfiltration unit 4 is measured by pressure indicators 14 and 16.

20 [0035] The microfiltration process is carried out at the target entity's isoelectric pH, a transmembrane pressure difference of less than 2 psi, an axial flow rate of less than 1 meter/second, and a permeation flux of less than 30 lmh.

25 [0036] After subjecting the polydisperse liquid to a microfiltration process, the microfiltration membrane is subjected to an acid-free cleaning regime. This is carried out by rinsing with deionized water at an axial flow velocity of 2 m/s for 5 minutes with the permeate ports fully opened. This is followed by recycling cleaning agents Ultrasil 10 – detergent at 0.5 wt. % and Ultrasil 02 surfactant at 0.1 wt. % at an axial velocity of 2 m/s at 45 °C for 30 minutes. The cleaning agents (Ultrasil 02, 10, Ecolab, St. Paul, MN) are then flushed from the system for 10 minutes with deionized water. This is followed by sterilization with 0.1 wt. % NaOCl at 40 °C for 10 minutes at 0.33 m/sec. This velocity was chosen to give sufficient residence time for the bleach to act on the membrane modules. The membranes are stored in this dilute

bleach solution until the next time the microfiltration process is to be carried out, before which the dilute bleach solution is flushed out by rinsing with deionized water for 10 minutes at 2 m/s velocity.

[0037] The ultrafiltration process can be carried out by utilizing an 5 ultrafiltration membrane under conditions effective to permit the target entity to be retained on the ultrafiltration membrane at a pH which differs from the target entity's pI. Typically, this involves carrying out the ultrafiltration process at a pH above that at which the target entity precipitates. Particularly suitable ultrafiltration process conditions are at a pH greater than 8.5, preferably greater than 10.

10 [0038] The ultrafiltration process can be carried out at an ionic strength of 10-20 mM NaCl, preferably 12-17 mM NaCl.

[0039] The ultrafiltration process can be carried out at a permeation flux of 110-130 lmh, preferably 115-125 lmh.

15 [0040] The target entity is selected from the group consisting of a protein, polypeptide, amino acid, colloid, mycoplasm, endotoxin, virus, carbohydrate, RNA, DNA, and antibody.

[0041] Where the target entity is a is protein or polypeptide, it can be selected 20 from the group consisting of glycoprotein, immunoglobulin, hormone, enzyme, serum protein, milk protein, cellular protein, and soluble receptor. Particularly suitable proteins or polypeptides are selected from the group consisting of alpha-proteinase inhibitor, alkaline phosphatase, angiogenin, antithrombin III, chitinase, extracellular superoxide dismutase, Factor VIII, Factor IX, Factor X, fibrinogen, glucocerebrosidase, glutamate decarboxylase, human serum albumin, insulin, myelin basic protein, lactoferrin, lactoglobulin, lysozyme, lactalbumin, proinsulin, soluble 25 CD4, component and complexe of soluble CD4, and tissue plaminogen activator.

[0042] The polydisperse liquid is milk produced by a transgenic animal. The transgenic animal is selected from the group consisting of a cow, goat, pig, rabbit, mouse, rat, and sheep.

[0043] Procedures for making transgenic animals are well known.

30 [0044] One means available for producing a transgenic animal (e.g., a mouse) is as follows: female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as M2

medium (Hogan B. et al. *Manipulating the Mouse Embryo, A Laboratory Manual*, Cold Spring Harbor Laboratory (1986), which is hereby incorporated by reference). A DNA or cDNA molecule is purified from a vector (such as plasmids pCEXV-alpha, pCEXV-alpha, or pCEXV-alpha) by methods well known in the art. Inducible 5 promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the transgene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the transgene. The DNA, in an appropriately buffered solution, is put into a microinjection needle (which may be made from 10 capillary tubing using a pipet puller), and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse (i.e., a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant), where it proceeds to the uterus, implants, and 15 develops to term. Alternatively, transgenic animals can be prepared by inserting a DNA molecule into a blastocyst of an embryo or into embryonic stem cells.

[0045] The polydisperse liquid can also be a cell culture fluid from transgenic plant cells. The transgenic plant cells are from plants, such as alfalfa, canola, rice, wheat, barley, rye, cotton, sunflower, peanut, corn, potato, sweet potato, bean, pea, 20 chicory, lettuce, endive, cabbage, cauliflower, broccoli, turnip, radish, spinach, onion, garlic, eggplant, pepper, celery, carrot, squash, pumpkin, zucchini, cucumber, apple, pear, melon, strawberry, grape, raspberry, pineapple, soybean, tobacco, tomato, sorghum, sugarcane, or banana.

[0046] Procedures for making transgenic plants are well known. In general, 25 methods of making recombinant plant cell(s) involve the introduction of recombinant molecules (e.g., heterologous or not normally present foreign DNA construct) into host cells (e.g., host cells of plant(s), plant tissues, etc.) via specific types of transformation. Thus, a DNA construct contains necessary elements for the transcription and translation in plant cells of a heterologous DNA molecule. The 30 DNA molecule, the promoter, and a 3' regulatory region can be ligated together using well known molecular cloning techniques as described in Sambrook et al., Molecular

Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, NY (1989), which is hereby incorporated by reference in its entirety.

5 [0047] The DNA construct can be incorporated into cells using conventional recombinant DNA technology. Generally, this involves inserting the DNA construct into an expression vector or system to which it is heterologous (i.e., not normally present). Once the DNA construct of the present invention has been prepared, it is ready to be incorporated into a host cell (e.g., bacteria, virus, yeast, mammalian cells, insect, plant, and the like).

10 [0048] One approach to transforming plant cells and/or plant cell cultures, tissues, suspensions, etc. with a DNA construct of the present invention is particle bombardment (also known as biolistic transformation) of the host cell. This technique is disclosed in U.S. Patent Nos. 4,945,050, 5,036,006, and 5,100,792, all to Sanford, et al., which are hereby incorporated by reference in its entirety.

15 [0049] Another method of introducing the gene construct of the present invention into a host cell is fusion of protoplasts with other entities, either minicells, cells, lysosomes, or other fusible lipid-surfaced bodies that contain the chimeric gene (Fraley, et al., Proc. Natl. Acad. Sci. USA, 79:1859-63 (1982), which is hereby incorporated by reference in its entirety).

20 [0050] The DNA construct of the present invention may also be introduced into the plant cells and/or plant cell cultures, tissues, suspensions, etc. by electroporation (Fromm, et al., Proc. Natl. Acad. Sci. USA, 82:5824 (1985), which is hereby incorporated by reference in its entirety).

25 [0051] Another method of introducing the DNA construct into plant cells and/or plant cell cultures, tissues, suspensions, etc. is to infect a plant cell with *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* previously transformed with the DNA construct.

30 [0052] Once a recombinant plant cell and/or plant cell cultures, tissues, suspensions, etc. are obtained, it is possible to regenerate a full-grown plant therefrom. Plant regeneration from cultured protoplasts is described in Evans et al., Handbook of Plant Cell Cultures, Vol. 1: (MacMillan Publishing Co., New York, 1983); and Vasil I.R. (ed.), Cell Culture and Somatic Cell Genetics of Plants, Acad.

Press, Orlando, Vol. I, 1984, and Vol. III (1986), which are hereby incorporated by reference in their entirety.

[0053] Another embodiment of the present invention is directed to a method of recovering a target entity from a polydisperse liquid by subjecting the 5 polydisperse liquid to a microfiltration process. The microfiltration process utilizes a microfiltration membrane under conditions effective to permit the target entity to pass through the microfiltration membrane as a permeate, where the target entity in the permeate is greater than 90% of the target entity present in the polydisperse liquid and the target entity is present in the permeate in a concentration of 7-10%. The operating 10 conditions of the microfiltration process and the target entity treated in that process are described above.

[0054] Yet another embodiment of the present invention is directed to a method of recovering a target entity from a polydisperse liquid by subjecting the polydisperse liquid to an ultrafiltration process. The ultrafiltration process utilizes an 15 ultrafiltration membrane under conditions effective to permit the target entity to be retained on the ultrafiltration membrane at a pH which differs from the target entity's pI. The operating conditions of the ultrafiltration process and the target entity treated in that process are described above.

20

EXAMPLES

Example 1 - Feed Suspension.

[0055] Transgenic goat milk was supplied by GTC Biotherapeutics, from their 25 goat farm in Central, MA. The average composition of the transgenic goat milk is shown Table 1.

Table 1. Composition and Properties of Transgenic Goat Milk

Composition (wt.%)

Fat: 3.5%; Proteins: 3.1% (80% casein, rest α -lactalbumin, β - lactoglobulin, Immunoglobulins); Lactose: 4.6%; Ash: 0.8%; Human IgG: 2 to 3 g/l; Total solids: 12%.

Salient properties

pH: 6.6 – 6.9; Target human IgG pI: 9.0; Casein pI: 4.6

Main component diameters

Fat: 1 to 20 μ m; Casein micelles: 0.3 – 0.4 μ m; IgG: 20 nm (155 kDa);

Other whey proteins: 15- 40 kDa

The human IgG concentration in the transgenic goat milk (~ 8 g/l) was diluted with non-transgenic milk to between 1.75 to 3.25 g/l.

5 **Example 2 - Membrane Modules.**

[0056] Tubular hollow fiber membrane were supplied by Millipore Corporation, Bedford, MA. Each module had six 0.1 μ m mean pore-size polyether sulfone hollow fibers of internal diameter 1.27 mm and pore diameter of 100 nm. For 10 the helical module, the fibers were wound in a single-wrap helix around an acrylic rod (Figure 1A). The lengths of the linear (L-3a) and helical (H-3a) modules were 18.5 and 13.5 cm, respectively. The corresponding filtration areas were 44 and 32 cm^2 .

15 **Example 3 - Flowsheet.**

[0057] The flow diagram of the labscale hollow fiber microfiltration system is given in Figure 1B. This system consists of two circulation loops – retentate and permeate. The retentate loop consists of the milk tank (any graduated tube of 50 ml capacity), a hollow fiber microfiltration module as described in Example 1, a 20 peristaltic pump (Masterflex, 7521, Cole Parmer, Chicago, IL), two pressure gauges (glycerine filled, 0- 60 psi, 1008, Aschcroft, Stratford, CT) upstream and downstream of the hollow fiber microfiltration module, a flowmeter (tube size #14, Gilmont, Barrington, IL), and a needle valve downstream of the flowmeter. The axial velocity of the retentate stream and the back pressure downstream of the microfiltration 25 module can be varied in this loop. The permeate circulation loop consists of the permeate tank (any glass graduated flask of 500 ml capacity), a peristaltic pump (Masterflex, 7521, Cole Parmer, Chicago, IL), and two pressure gauges (glycerine filled, 0- 60 psi, 1008, Aschcroft, Stratford, CT) upstream and downstream of the

hollow fiber microfiltration module. By adjusting the rpm of the peristaltic pump in the permeate circulation loop, the pressure drop in the tube and shell side of the hollow fiber microfiltration module can be made nearly equal by coflow permeate circulation in the shell side of the microfiltration module. This facilitates a low 5 uniform TMP along the microfiltration module. Without the permeate circulation loop, the TMP and the axial velocity cannot be independently varied. A high axial velocity would lead to a high pressure upstream of the microfiltration module leading to a high non-uniform TMP along the microfiltration module. The hold up volume in the retentate loop is 85 ml, whereas in the permeate loop it was between 25 and 50 ml 10 depending on the microfiltration module used.

Example 4 - Diafiltration Experiments.

[0058] A series of diafiltration experiments (4 to 6 diavolumes) with pH 15 adjusted deionized water were conducted to study the IgG transmission and permeation flux behavior with the passage of diafiltration and with respect to variation in operating pH, TMP, concentrating factor, module type, and axial velocity. For the pH experiments, the pH of milk was adjusted to the values 7.5, 8, 8.5, and 9 by adding requisite quantities of 0.25 M NaOH solution according to the milk pH 20 calibration graph prepared earlier ($pH = 2.857[\text{NaOH}](\text{g/l}) + 6.7436$, $R^2 = 0.99$). The base values of the other variables were 2.5 psi uniform TMP, axial velocity of 1.1 m/sec, 1X milk concentration, and short helical module. To study the effect of TMP, the TMP was varied from 2 psi to 4.5 psi at the optimum pH determined in the 25 previous step. Milk at concentrations corresponding to 1, 1.25, 1.5, 1.75, and 2 times the normal milk concentration were used to investigate the effect of concentrating factor on protein transmission. For 1X concentration, diafiltration was started after flushing the system with milk. For 2X concentration, one system volume was collected prior to diafiltration, while maintaining a constant reservoir level with milk addition. The permeate volumes collected in the concentration phase for 1.25X, 1.5X, 30 1.75X, and 2X were 0.25, 0.5, 0.75, and 1 times the retentate loop volume, respectively. To compare the efficacy of the linear module with the helical module, experiments were conducted in the diafiltration mode at five concentrations corresponding to 1, 1.25, 1.5, 1.75, and 2 times the normal milk concentration with

the short linear module. Samples (1 ml) were taken from the retentate and permeate streams at regular intervals and analyzed for IgG and protein concentrations. Finally, the effect of axial velocity on the target protein transmission was studied using a short helical module at 1X milk concentration, 2 psi uniform TMP, pH=9, and velocities 5 ranging from 0.85 to 1.2 m/sec ($Re \approx 830 - 1170$, $Re = 2a u_{ave.} / \nu$, where $2a$ (m) is the internal diameter of the membrane bore, u_{ave} (m/s) is the average axial velocity in the membrane bore and ν (m²/s) is the kinematic viscosity of milk). All experiments were conducted in the laminar axial flow regime.

10 **Example 5 - IgG Assay and Yield.**

[0059] This assay is based on the protocol supplied by GTC Biotherapeutics, (Framingham, MA) which is described as follows. Protein A affinity chromatography (PA ImmunoDetection™ sensor cartridge (2.1 x 30 mm), PerSeptive Biosystems, 15 Framingham, MA) was used to obtain IgG concentrations in the various goat milk streams. 1.5 ml of milk samples were pipetted into 2 ml Eppendorf centrifuge tubes and centrifuged at 21000g for 30 min. The milk separated into a top fat layer, a clear whey solution, and a casein pellet. 0.75 ml of the clear whey phase was carefully extracted with a pipette after puncturing the fat layer. This was pipetted into 20 centrifuge tubes (catalog # 8163, Spin-X tubes, Corning, NY) with 0.45 µm pore size cellulose acetate membranes and were centrifuged at 21000g for 15 min. The clarified permeate was then injected into the HPLC column. For the permeate samples, sample preparation was unnecessary. A HPLC (Waters 510 with Millennium 2010 operating system) with a 486 UV detector and U6K sample injector 25 were used (Waters Corp., Milford, MA). The loading buffer was 10 mM phosphate buffer, 150 mM NaCl at pH 7.20 ± 0.05 and the elution buffer was 12 mM HCl with 150 mM NaCl. The pump flow rate was set at 2 ml/min. and the detector wave length at 280 nm. The injection volume was 10 µL for milk and 20 to 40 µL for permeate samples. A calibration graph was constructed by injecting different dilutions of IgG 30 fusion protein (GTC Biotherapeutics, Framingham, MA). Loading buffer was passed through the column for 10 minutes followed by sample injection and loading buffer again for 5 minutes. After this, elution buffer was run for 10 minutes. A clean peak

corresponding to IgG fusion protein was detected at around 6.5 minutes into the elution phase. Area obtained by peak integration was compared with the calibration graph to obtain the IgG concentration of the sample after dividing by the sample volume. Care was taken to ensure that all readings were within the range of the 5 calibration graph. This was done by adjusting the sample injection quantities. This system has an efficiency of 95% as reported by GTC. There was also some variability in the IgG concentration obtained from milk samples due to small errors in pipetting out the clear solution after centrifuging. The yields for these experiments were computed based on applying a factor of 1.05 to the highest reading of 3.1 g/l obtained 10 from a milk sample with the IgG product. This gives a starting IgG concentration of 3.25 g/l for milk. The yield for a diafiltration experiment was calculated with the formula

$$Y = (N_d \langle C_p \rangle) / 3.25 X, \quad (2),$$

15

where N_d is the number of diavolumes, $\langle C_p \rangle$ is the average permeate IgG concentration, and X is the concentration factor of milk prior to diafiltration.

Example 6 - Protein Assay.

20 [0060] The Bradford assay (# 500-0006, Bio-Rad, Hercules, CA) was used to determine protein concentration. Bovine lyophilized casein powder (C7891, Sigma, St. Louis, MO) was used as a standard and readings were taken in disposable 5 ml polystyrene cuvettes (# 223-9950, Bio-Rad). The absorbance readings with the 25 spectrophotometer (U-2000, Hitachi, Japan) were taken in the visible range at 595 nm wavelength.

Example 7 - Fat Assay.

30 [0061] Fat content was measured by the Gerber method which is approved for use by dairies in USA. 11 ml of preheated milk sample (37°C) was added to 10 ml of sulfuric acid in a butyrometer. 1 ml of amyl alcohol was added and the butyrometer was capped with a special stopper. Shaking the butyrometer ensures digestion of the

proteins by sulfuric acid. The butyrometer was then inverted and centrifuged for 6 minutes at 350g. After this, the butyrometer was immersed in a water bath at 65°C for 5 min. The fat appeared as a clear liquid and the quantity was read out as a volume percentage in the graduated section of the butyrometer.

5

Example 8 - Cleaning Regimen.

[0062] The following cleaning protocol was used. After each experiment, the 10 coflow pump and tubing were detached and the system was rinsed with deionized water at 50 °C at an axial flow velocity of 1.3 m/s for 1 minute with the permeate ports fully opened. This was followed by recycling cleaning agents Ultrasil 10 – detergent at 0.5 wt. % and Ultrasil 02 – surfactant at 0.1 wt. % at an axial velocity of 1.3 m/s at 50 °C for 30 minutes. The loss in volume due to permeation was made up by addition of deionized water at 55 °C. The cleaned membrane deionized water 15 fluxes are plotted in Figure 3. This indicates very good flux recovery from run to run.

[0063] A series of experiments to evaluate base values of variables was first run. Then, the optimization strategy described in Figure 2 was followed to successively optimize the yield of the target protein, one variable at a time.

20 **Example 9 - Initial Experiments.**

[0064] Several experiments were conducted to evaluate the yield of the target protein (IgG) with various TMP's, linear, helical and ceramic microfiltration modules, with and without coflow and at different pH values. These results are shown in Table 25 2.

Table 2. Initial Yields of IGG

Product	Module ^a	Conc. ^b	Mode ^c	pH ^d	Yield(%) ^e
IgG	Linear	1X	Standard	6.8	0.7
IgG	Helical	1X	Coflow	6.8	3

IgG	Ceramic	1X	Coflow	6.8	3.6
IgG	Helical	1X	Standard	9	9
IgG	Ceramic	1X	Coflow	9	36

5 a) Linear: Traditional linear hollow fiber module; Helical: Specially designed hollow fiber module where the fibers are helically wound around a support rod. Relatively short linear (L-3a) and helical (H-3a) modules were chosen.

10 b) Concentration: Factor by which the milk is concentrated in the experiment. 1X means the normal concentration of milk.

10 c) Standard: Normal mode of crossflow membrane filtration where the feed is circulated axially in the bore of the hollow fibers and the permeate at atmospheric pressure is drawn from the shell side of the hollow fiber module; Coflow: special mode of crossflow membrane filtration where the permeate is circulated in the shell side in the same direction as the retentate, resulting in similar pressure drops in the bore of the tube and shell side leading to approximately uniform transmembrane pressure in the axial direction of the hollow fiber membrane module.

15 d) pH of the milk feed and diafiltration buffer.

15 e) Yield: Ratio of the mass of product harvested in the permeate by the mass of product fed into the system.

20 The yield values were very low for the first four cases with a large improvement for the experiment conducted at pH = 9.0, the isoelectric point of the target IgG as confirmed by GTC Biotherapeutics. This demonstrated that the operating pH was indeed a very important variable.

25 **Example 10 - Microfiltration Optimization Experiments.**

[0065] A series of pH experiments were conducted with the short helical module (H-3a, area = 32 cm²) with co-flow at a uniform TMP of 2.5 psi, 1X milk concentration, and axial velocity of 1.1 m/sec (Re \cong 1075). The average permeation flux increased more than threefold from below 10 to over 30 lmh as the pH was raised from the physiological value of 6.8 to 9.0, isoelectric point of the target IgG (Figure 4A). IgG yield increased dramatically from 0.7% to around 70% with increase in pH (Figure 4B). This confirmed applicants' hypothesis of high transmission of target protein at its pI and is consistent with the results reported by other researchers (Burns et al., "Effect of Solution pH on Protein Transport through Ultrafiltration

Membranes," *Biotech. & Bioengg.* 64:27-37 (1999) and Burns et al., "Contributions to Electrostatic Interactions on Protein Transport in Membrane Systems," *AIChE J.* 47:1101-14 (2001), which are hereby incorporated by reference in their entirety).

This is due to a low value of electrical potential of the target molecules leading to

5 lower exclusion from membrane pores and cake interstices. It was decided to set the operating pH at 9.0. Higher values of pH were not considered as it was deemed better to retain an operating pH as close to the physiological pH of milk which is 6.8.

[0066] However, to further increase the product yield, experiments were conducted to improve the mass transfer characteristics of the system. Several

10 experiments were conducted with the short helical module (H-3a, area = 32 cm²) at pH 9.0, 1X milk concentration, axial velocity of 1.1 m/sec (Re \approx 1075), and uniform TMP's in the range of 2 – 4.5 psi (Figure 5). The average permeation flux varied linearly with TMP. This confirmed applicants' selection of the operating regime as the pressure-dependent regime, where the permeation flux varies linearly with TMP

15 (Figure 6). In this regime, the cake deposit on the membrane was expected to be sparse thereby facilitating good protein transmission. This hypothesis was confirmed by the experimental results. At 2 psi, 95% yields were achieved, in duplicate, whereas at the higher TMP of 4.5 psi the yield dropped to just 40%. The permeation flux, on the other hand rose with increasing TMP, from 16 to 50 lmh. As the product, 20 in this case, is costly, a very high yield with a low permeation flux is considered more desirable than a low yield with a high permeation flux. Hence, the optimum uniform TMP is selected as 2 psi giving an average permeation flux of 16 lmh and 95% yield after four diavolumes. For other products, an optimization exercise could be carried out to obtain the desired combination of high flux with reasonable product yields.

25 [0067] A series of diafiltration experiments with different feed milk concentration factors of 1X to 2X were then conducted with a short helical module (H-3a, area = 32 cm²) at pH 9.0, uniform TMP of 2 psi, and axial velocity of 1 m/sec.

The average yield for these experiments was over 95% (Figure 7A). Four diavolumes were sufficient for the 1X experiment whereas 5 to 6 diavolumes were necessary for 30 the experiments with higher concentration. Concentration was achieved by incorporating a concentration step prior to diafiltration with deionized water at pH 9.0. For instance, 2X concentration was achieved by adding milk instead of deionized

water for the first diavolume to the reservoir. At higher milk concentrating factors, the average permeation flux decreases and the number of diavolumes to achieve an IgG yield of 95% goes up. However, this is balanced out by the fact that at larger milk concentrations, a higher mass of product protein is recovered. Thus, there is a
5 need to optimize the milk concentrating factor, to obtain the condition where the product recovery per unit time is maximized. To obtain the optimum diafiltration conditions Ng et al., "Optimization of Solute Separation by Diafiltration," *Sep. Sci.* II(5):499-502 (1976), which is hereby incorporated by reference in its entirety), a plot was constructed between diafiltration time/milk concentration factor, T/X, and milk
10 concentration factor, X (Figure 7B). This accounts for the higher quantities of milk processed at higher concentrations. The minimum of this plot gives the best operating point, that is, ~1.75X.

15 [0068] To compare the efficiency of the linear module with the helical module, similar experiments were conducted in the diafiltration mode at various milk concentrating factors, with the short linear module with all the other variables at the previously determined optimal values (Figure 7A). Except for 1X concentration, where the yield was in excess of 95%, for all the other concentrations the yields were moderate (60 to 75%). This clearly indicates that the linear module was not as effective as the helical module for handling concentrated suspensions. This was
20 possibly due to the greater concentration of fat globules at the membrane wall for the linear modules which operate at a lower wall shear rate at the same axial velocity as the helical modules.

25 [0069] Finally, the effect of axial velocity was evaluated with the short helical module (H-3a; area = 32 cm²) at pH 9.0, uniform TMP of \leq 2 psi, 1X milk concentration, and various axial velocities in the range 0.85 to 1.2 m/sec corresponding to Reynold's numbers 830 to 1170 (Figure 8). 95% yield was obtained for velocities \geq 0.95 m/sec. The best operating velocity was 0.95 m/sec (Re \cong 930).

30 [0070] Thus the optimum conditions determined were pH 9.0, uniform TMP of 2 psi, 1.75 X milk concentration factor, helical module, and 0.95 m/sec. axial velocity resulting in 95% yield of the target IgG.

[0071] The methodology reported here demonstrates that by combining optimum fluid mechanics with optimum electrostatics, the yield of a target protein

from a highly complex polydisperse suspension like whole transgenic goat milk could be raised from an extremely low initial value of 0.7% to a value of 95%. The following are recommended:

1. Use a short path length microfiltration module.
- 5 2. Operate at a low uniform TMP.
3. Operate with the helical hollow fiber microfiltration module at the combination of all the optimizing conditions reported here to obtain low membrane fouling and high yield of the target protein.
4. Start-up so that the permeation flux is in the region of 10 lmh
- 10 (for the helical module) and does not rise above this value even transiently, by adjusting the TMP. The permeation flux rises as diafiltration proceeds, to give an average value of around 15 lmh due to decrease in feed viscosity and solids concentration.
- [0072] The results presented here demonstrate that high product recoveries are
- 15 possible in microfiltration of complex poly-disperse suspensions by careful control of the various parameters and selection of the appropriate module geometry as detailed in the methodology presented here. The helical microfiltration module appears to be superior to the commercially available linear version when handling concentrated suspensions. The results and the methodology described here should be
- 20 generalizeable to other complex suspensions of biological origin.

Example 11 - Ultrafiltration Optimization Experiments

[0073] The scheme employed for the ultrafiltration (UF) step is shown in

25 Figure 9. The permeate obtained after microfiltration of transgenic milk contains the desired product at a purity (mass ratio of product to total protein) of about 7%. The UF step is proposed to raise the purity to 80% with a yield of 80% to give an overall process yield of 75% and a purity of 80% for the combined MF/UF process. A selectivity (defined as the ratio of the observed sieving coefficients of the other whey

30 proteins and the target IgG) of 18 and a purification factor (defined as $P = (\text{Final concentration of IgG in the retentate}/\text{Initial concentration of IgG in the retentate})/(\text{Final concentration of non-IgG proteins in the retentate}/\text{Initial concentration of non-IgG proteins in the retentate})$) of 50 to achieve this. This is based on mass balance of

solutes (van Reis et al., "Optimization Diagram for Membrane Separations," *J. Membr. Sci.* 129:19-29 (1997), which is hereby incorporated by reference in its entirety). The target IgG (155 kDa molecular weight) has a pI of 9 whereas the predominant whey proteins have pI's in the range of 4.5 to 5.2 (MW 14 to 36 kDa).

5 The usual practice would be to adjust the feed pI to around 5 so that IgG gets retained in the 100 kDa cut off UF membrane whereas the other proteins readily permeate through based both on size and charge.

[0074] This cannot be readily applied here, because of precipitation at pH below 8.5. To increase protein solubility (salting in) 100 mM NaCl was added. Thus, 10 it was possible to do the UF at pH ranging from 5.2 to 11. It was found that high selectivities were achieved at pH values of 10.75 and 5.85. A pH of 10.75 was chosen as a much higher flux could be obtained in comparison with pH 5.85 (Figure 10). Apart from pH, the other two optimizing variables were ionic strength and permeation flux. At any pH, high ionic strength leads to increase charge shielding and thinner 15 double layers around the protein molecules. At pH 11, the optimum ionic strength was 20 mM NaCl (Figure 11). The corresponding value at pH 10.75 was 15 mM NaCl. A higher ionic strength leads to greater passage of IgG leading to lower selectivity and loss of product whereas a lower ionic strength leads to lower passage of IgG but the other whey proteins as well which are far away from their pI's of 20 around 4.5 to 5.2. Thus, an ionic strength of less than 15 mM leads to low selectivity between IgG and other whey proteins as both species are retained to a large degree. The effect of permeation flux is subtle. A low flux will lead to a sparse cake as elucidated in the aggregate transport model (Baruah et al., "A Predictive Aggregate Transport Model for Microfiltration of Combined Macromolecular Solutions and 25 Poly-Disperse Suspensions: Model Development," *Biotechnol. Progress*, 19:1524-32 (2003) and Baruah et al., "A Predictive Aggregate Transport Model for Microfiltration of Combined Macromolecular Solutions and Poly-Disperse Suspensions: Testing Model with Transgenic Goat Milk," *Biotechnol. Progress*, 19:1533-40 (2003), which are hereby incorporated by reference in their entirety) on 30 the membrane and lead to higher permeation of the bigger IgG molecules leading to a low selectivity and low yield. Again, at very high permeation rates, IgG leaks out through the UF membrane because of the higher IgG concentration at the wall, high

pressure differential, and high concentration difference across the membrane. Hence, an intermediate permeation flux (120 lmh) leads to low IgG transport coupled with a moderate transport of other whey proteins leading to the favorable combination of high selectivity, yield and purity (Figures 12, 13, and 14). The projected yield and 5 purification factor of IgG based on extrapolation in time are shown to exceed the required values of 80% each for pH 10.75. (Figure 15).

[0075] Although the invention has been described in detail for the purpose of illustration, it is understood that such details are solely for that purpose and variations can be made therein by those skilled in the art without departing from the spirit and 10 scope of the invention which is defined by the following claims.